Compare INSE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | MDWD |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.3M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | INSE | MDWD |
|---|---|---|
| Price | $8.92 | $18.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $13.50 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 182.0K | 95.3K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $309,900,000.00 | $20,932,000.00 |
| Revenue This Year | $4.17 | $15.89 |
| Revenue Next Year | N/A | $25.33 |
| P/E Ratio | $4.66 | ★ N/A |
| Revenue Growth | 4.98 | ★ 6.15 |
| 52 Week Low | $6.51 | $14.14 |
| 52 Week High | $11.61 | $22.51 |
| Indicator | INSE | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 57.25 |
| Support Level | $8.79 | $18.55 |
| Resistance Level | $9.34 | $19.05 |
| Average True Range (ATR) | 0.42 | 0.57 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 55.52 | 71.67 |
Inspired Entertainment Inc is a gaming technology company based in the United States. Its core business involves the development of Virtual Sports and Server-Based Gaming systems with associated terminals and digital content to regulate betting, gaming, and lottery operators around the world. It operates through four segments, namely Gaming, Virtual Sports, Interactive, and Leisure. The company generates maximum revenue from the Gaming segment. Its Gaming segment supplies gaming terminals as well as gaming software and games for the terminals provided to betting offices, casinos, gaming halls, and high street adult gaming centers. Geographically, it derives a majority of revenue from the UK.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.